Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
4.190
-0.250 (-5.63%)
At close: Dec 20, 2024, 4:00 PM
4.210
+0.020 (0.48%)
After-hours: Dec 20, 2024, 5:01 PM EST
Verastem Revenue
Verastem had revenue of $10.00M in the twelve months ending September 30, 2024.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
12.67
Revenue / Employee
$136,986
Employees
73
Market Cap
186.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accuray | 444.20M |
Amarin Corporation | 241.02M |
Organigram Holdings | 118.32M |
ADC Therapeutics | 70.72M |
KORU Medical Systems | 31.99M |
Myomo | 25.24M |
Orchestra BioMed Holdings | 2.65M |
Quantum-Si incorporated | 2.27M |
VSTM News
- 3 days ago - Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
- 24 days ago - Verastem: Preparing For Upcoming Catalysts - Seeking Alpha
- 25 days ago - Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 6 weeks ago - Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - Business Wire
- 7 weeks ago - Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - Business Wire
- 7 weeks ago - Verastem Oncology to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - Business Wire
- 2 months ago - Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - Business Wire